179 results on '"Pannee, Josef"'
Search Results
2. Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides
3. Abeta CSF LC-MS
4. Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70
5. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
6. SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration
7. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements
8. Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
9. Plasma Aβ ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
10. Plasma metabolomics of presymptomatic PSEN1 ‐H163Y mutation carriers: a pilot study
11. The global Alzheimer's Association round robin study on plasma amyloid β methods
12. Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults.
13. Reference measurement procedures for Alzheimerʼs disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
14. Ultra‐performance liquid chromatography‐tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture
15. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
16. Plasma metabolomics of presymptomatic PSEN1-H163Y mutation carriers: A pilot study
17. P4-473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX Aβ PEPTIDES IN HUMAN CEREBROSPINAL FLUID
18. F1‐05‐03: THE 1946 COHORT: RELATIONSHIPS BETWEEN CEREBRAL AMYLOID PATHOLOGY USING TWO INDEPENDENT METHODS FOR PLASMA AMYLOID BETA MEASUREMENT
19. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ 42 IN HUMAN CEREBROSPINAL FLUID
20. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species
21. Additional file 2: Figure S2. of Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
22. CERTIFICATION REPORT: The certification of Amyloid β1-42 in CSF in ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC
23. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements
24. Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases
25. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species
26. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update
27. USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42
28. [P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‐AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS
29. PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42
30. CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation
31. Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure
32. Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
33. Mass spectrometric quantification of amyloid-beta in cerebrospinal fluid and plasma
34. Tracking reactive astrocytes in autosomal dominant Alzheimer disease with plasma GFAP and multi‐modal PET imaging.
35. Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases.
36. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
37. TOWARD RE-CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID
38. A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX Aβ PEPTIDES IN HUMAN CEREBROSPINAL FLUID
39. THE 1946 COHORT: RELATIONSHIPS BETWEEN CEREBRAL AMYLOID PATHOLOGY USING TWO INDEPENDENT METHODS FOR PLASMA AMYLOID BETA MEASUREMENT
40. Specific Triazine Herbicides Induce Amyloid-β42 Production
41. Reference measurement procedure for CSF amyloid beta (Aβ)1-42and the CSF Aβ1-42/Aβ1-40ratio - a cross-validation study against amyloid PET
42. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
43. P4-313: Commutability of the Candidate Certified Reference Materials for the Standardization of Aβ1-42 Measurements in Human Cerebrospinal Fluid
44. Improved concordance between [11C]PIB PET and CSF Aβ42 using Aβ42/Aβ40: findings from a multicentre European memory clinic population
45. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements
46. Round robin test on quantification of amyloid‐β 1–42 in cerebrospinal fluid by mass spectrometry
47. P4-231: Commutability of candidate reference materials for the harmonization of Aβ1-42 measurements, on behalf of the ifcc working group on CSF proteins
48. P1-033: A candidate reference method for analysis of amyloid beta 1-42 (Aß1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer
49. Corrigendum to “The amyloid-beta degradation pattern in plasma—A possible tool for clinical trials in Alzheimer’s disease” [Neurosci. Lett. 573 (2014) 7–12]
50. P4-226: CSF Aβ42/40 and Aβ42/38 ratios by prm mass spectrometry or elisa: Improved biomarkers of Alzheimer's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.